REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Based on the overall results from the Phase 1 part of the study the sponsor decided to end the study. The decision was not due to safety reasons.

Conditions

Melanoma
Merkel Cell Carcinoma
Triple Negative Breast Cancer
Head and Neck Squamous Cell Carcinoma
Renal Cell Carcinoma
Colorectal Cancer
Sarcoma

Interventions

DRUG: NKTR-262
DRUG: bempegaldesleukin
DRUG: nivolumab

Sponsor

Nektar Therapeutics